EXCLUSIVE-NETWORKS
9.1.2020 07:02:05 CET | Business Wire | Press release
Exclusive Networks today announced the appointments of four new Senior Vice Presidents to complement its existing global leadership team. The appointments of Gerard Allison (SVP, EMEA), Brad Gray (SVP, APAC), Scott Lewis (SVP, Americas) and Barrie Desmond (SVP Marketing & Communications) will provide strategic in-theatre leadership, supporting the company’s continuing success in offering unique local and global value, whilst driving future growth through market leading technologies, innovative services, and disruptive business models, creating value at scale for both vendors and channel partners alike.
“Gerard, Brad, Scott and Barrie are highly experienced operators who will make a valuable contribution to our business in 2020 and beyond,” said Olivier Breittmayer, CEO of Exclusive Networks. “Their arrival coincides with an exciting period of business transformation and innovation as we continue to scale-up and optimise our operational processes for renewed growth in disruptive service offerings, product portfolios and business models.”
Gerard Allison is a highly experienced senior executive with a 30+ year track record of building successful teams in EMEA, working at vendors such as Juniper Networks and, most recently, Gigamon. His extensive expertise and knowledge of the IT and security markets, commercial astuteness, entrepreneurial vision, relationship building and management skills, brings a wealth of experience to the EMEA business.
Brad Gray is a highly experienced senior executive with a 25+ year track record of building successful teams in APAC at vendors such as Juniper Networks, Polycom and, most recently, SAP. Having resided for 20 years in Singapore and for 3 years previously in Indonesia, Brad’s cultural, technological and commercial insights within the region brings a wealth of knowledge and expertise to the APAC business. His appointment comes as the former ‘Asia’ and ‘Pacific’ regions of Exclusive Networks combine as a single ‘APAC’ region.
Scott Lewis is a highly experienced senior executive with a 25+ year track record of regional sales and operations leadership in the Americas, having spent nearly 20 years in the cybersecurity sector working at vendors such as Blue Coat and IBM Internet Security Systems (ISS). Scott joins Exclusive from Fortinet where he spent the last 7 years leading its US Enterprise sales organisation and most recently its US West sales teams.
Barrie Desmond returns to Exclusive following a 12 month sabbatical having previously spent 7 years as Group Marketing Director and most recently as Chief Operations Officer. Barrie has over 30 years experience in marketing, communications and business development, having held senior management roles within channel and vendor organisations, with specialist knowledge and expertise in disruptive technologies and services in cybersecurity and cloud.
The new SVPs bring a wealth of expertise and experience to Exclusive Networks having held senior regional leadership roles at leading global channel and vendor organisations. Each report to Andy Travers, Executive Vice President, Worldwide Sales and Marketing.
“Our global footprint is significant and continually expanding, which emphasises the need for strong leadership at both local and regional levels,” said Andy Travers. “Gerard, Brad, Scott and Barrie are proven business leaders with a strong track record of success and I look forward to working closely with them to take advantage of the growth opportunities within their respective regions.
Their vast experience, knowledge and skills will be a tremendous asset to our business, our partners and our people as we continue to scale-up into a new decade.”
-ends-
About Exclusive Networks
Exclusive Networks is the global specialist VAD for cybersecurity and cloud solutions – the defining and interdependent technologies of the digital era. Its capabilities are backed by best-of-breed vendor portfolios, unparalleled skills and a host of compelling services from pre and post-sales technical support to leasing, training, professional services and global project management. With 50+ offices across five continents and presence in over 100 countries, Exclusive Networks has a unique ‘local sale, global scale’ model, enabling partners to achieve global reach, while delivering the added value of a locally-focused specialist distributor. More at www.exclusive-networks.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005671/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom